

Special Issue

Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications

Message from the Guest Editors

This Special Issue of *Metabolites* entitled “Advances in Metabolomics for Precision Medicine: From Biomarker Discovery to Clinical Applications” will be dedicated to identifying and addressing the most current challenges and successes in utilizing metabolomics independently or alongside other ‘omics’ technologies for diagnosing diseases and following patients post intervention to treat their disease. In addition to clinical studies, basic research including animal models and cell culture studies will also be included to provide a robust picture of the latest results in the field. New bioinformatics approaches for data analysis and tools to analyze large data sets are of interest and will also be considered for this Special Issue.

Guest Editors

Dr. Adam D. Kennedy

Metabolon, Inc., Morrisville, NC 27560, USA

Dr. Greg Michelotti

Metabolon, Inc., Morrisville, NC 27560, USA

Deadline for manuscript submissions

closed (28 February 2026)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/225513

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).